SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Yul Brynner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientYul Brynner
Date of birth1920-07-11
IdentifiersMRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572
Document date1983-10-27
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Adult preventive visit; rash improving. [S]

History of Present Illness

Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe on first-line pembrolizumab every 3 weeks (two cycles so far) and zoledronic acid every 12 weeks, who comes for his yearly preventive visit, timed before the respiratory virus season. The rash seen last week is fading with the triamcinolone cream, and the itching is much less; he has used cetirizine on three nights. He has had no new symptoms of immune-related side effects. His voice is stronger after the injection medialization and voice therapy, and he has begun rehearsing two hours a day; he hopes to rejoin the tour for a few performances a week next month. He saw the palliative care team four weeks ago and found it useful. He completed the health risk assessment before the visit. [S]

ElementDetail
VisitAdult preventive visit
Active treatmentPembrolizumab every 3 weeks; zoledronic acid every 12 weeks; vitamin D3 daily
Interval changeRash fading on topical steroid; no other immune-related symptoms
WorkRehearsing two hours a day; plans a graded return to the tour
SupportsSpouse, company manager, and the palliative care team

Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]

DomainFinding
Self-rated healthGood, apart from tiring by evening
PsychosocialWorried about the future but coping; strong sense of purpose in returning to the stage; supportive spouse and company
TobaccoFormer smoker; no tobacco for 12 years
Alcohol and drugsA glass of wine two or three nights a week (AUDIT-C 2); no other drug use
Physical activityWalks 30 minutes most days and does stage warm-ups
NutritionEating well; weight stable at about 72 kg
SleepAbout seven hours a night; itching woke him twice last week
Activities of daily livingIndependent
Instrumental activities of daily livingIndependent; company manager handles travel bookings
Home and travel safetySmoke detectors at home; seat belt always; hotel rooms booked near elevators
FallsNone
Hearing and visionReading glasses; no hearing difficulty

Review of Systems

SystemResultFinding
ConstitutionalPositiveTires by evening; no fever, night sweats, or weight loss since starting treatment
EyesNegativeNo redness or change in vision
Ears, nose, mouth, and throatPositiveVoice still slightly breathy after a long rehearsal; no mouth sores
CardiovascularNegativeNo chest pain, palpitations, or ankle swelling
RespiratoryPositiveOccasional dry cough in the morning; mild breathlessness on two flights of stairs, unchanged
GastrointestinalNegativeNo diarrhea, abdominal pain, or blood in the stool
GenitourinaryNegativeNo urinary symptoms
MusculoskeletalNegativeNo back, hip, or rib pain
IntegumentaryPositiveRash fading; mild itch
NeurologicalNegativeNo headache, weakness, or numbness
PsychiatricNegativeMood steady; PHQ-2 score 1
EndocrineNegativeNo heat or cold intolerance or excessive thirst

12 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeksEvery 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panelIntravenous route1983-09-22activeS
Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastasesEvery 12 weeks, after calcium and creatinine, with a dental examination done firstIntravenous route1983-10-13activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acidOne tablet by mouth dailyOral route1983-10-13activeS
Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds)Apply a thin layer twice daily for up to two weeksTopical route1983-10-20activeS
Cetirizine 10 mg oral tablet, one tablet daily as needed for itchingOne tablet by mouth daily as needed for itchingOral route1983-10-20activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1983-10-27Body height178cmS
1983-10-27Body weight72.3kgS
1983-10-27Body mass index (BMI) [Ratio]22.8kg/m2S
1983-10-27Systolic blood pressure124mm[Hg]S
1983-10-27Diastolic blood pressure76mm[Hg]S
1983-10-27Heart rate74/minS
1983-10-27Respiratory rate16/minS
1983-10-27Body temperature36.6CelS
1983-10-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1983-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1983-10-27Total score [AUDIT-C]2{score}S

Physical Exam

Vital signs recorded on 1983-10-27; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell, upright, and commanding; weight 72.3 kg, BMI 22.8
EyesPupils equal and reactive; conjunctivae normal
Ears, nose, and throatVoice louder and less breathy than at presentation; oral mucosa normal; good dentition
NeckNo supraclavicular or cervical nodes; thyroid not enlarged
CardiovascularRegular rhythm at 74 per minute; no murmur; no edema
RespiratorySlightly reduced breath sounds at the left apex; no wheeze or crackles
AbdomenSoft and non-tender; no liver enlargement
MusculoskeletalNo spinal, pelvic, or rib tenderness
SkinFading pink macules on the chest and back; no new lesions; no suspicious moles
NeurologicalAlert and oriented; normal strength and gait
PsychiatricComposed and engaged; good insight

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.
Immune-related maculopapular rash from pembrolizumab, grade 1 (about 8 percent of body surface area, itchy, no blisters or mucosal involvement)activeconfirmed L27.0S — Synthetic common immune-related adverse event on checkpoint inhibitor therapy.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Influenza vaccine, this seasonCompleted todayInactivated vaccine given today; safe on checkpoint inhibitor therapy
Pneumococcal vaccineCompleted todayPCV20 given today; recommended once for all adults 50 and older
Recombinant zoster vaccineCompleted todayDose 1 given today; dose 2 in two to six months
COVID-19 vaccine, this seasonDueRecommended; at his pharmacy next week, spaced from today's vaccines at his request
RSV vaccineDueRecommended at 60 to 74 for adults at increased risk, which his lung cancer confers; planned for the next visit
Tetanus, diphtheria, and pertussis boosterUp to dateTdap six years ago
Colorectal cancer screeningDueRecommended at 45 to 75; deferred by shared decision while he starts treatment for metastatic cancer; to be revisited after the first response scan
Prostate cancer screeningDeclinedIndividual decision at 55 to 69; after discussion he declined PSA testing while on cancer treatment
Lung cancer screeningNot indicatedHe has lung cancer and is followed with response imaging
Abdominal aortic aneurysm screeningNot indicatedOne-time ultrasound for men 65 to 75 who have ever smoked; he is 63, and his staging CT showed a normal abdominal aorta
Hepatitis C and HIV screeningUp to dateOne-time screening for both done in the past, negative
Cholesterol screening and statin decisionDueDeferred by shared decision while he starts treatment for metastatic cancer
Diabetes screeningUp to dateGlucose is checked before each pembrolizumab infusion; 94 to 104 mg/dL
Blood pressure screeningCompleted today124/76 mmHg
Depression screeningCompleted todayPHQ-2 score 1; PHQ-9 4 two weeks ago
Unhealthy alcohol use screeningCompleted todayAUDIT-C 2, below the risk threshold
Tobacco useCompleted todayFormer smoker; no tobacco for 12 years
Skin examinationCompleted todayRash fading; no suspicious lesions

Immunizations given today: Influenza vaccine, 1983-1984 season; Pneumococcal conjugate vaccine PCV20, single dose; Recombinant zoster vaccine, dose 1 of 2 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Cycle 3 of pembrolizumab next week. COVID-19 vaccine at the pharmacy next week. Response CT in about four weeks. RSV vaccine and zoster dose 2 at later visits. Next preventive visit in one year. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 30 minutes, with his consent, building on the goals-of-care conversation with the palliative care team. We talked about what metastatic lung cancer can mean, that treatment aims to control it and help him live well for as long as possible rather than to cure it, and why it helps to plan ahead while he is well. He named a health care agent, who is recorded in the chart and not named here, and took a health care proxy form and a living will form home. He said what matters most to him is to keep working on the stage for as long as he can and to be told the truth plainly. He wants full cancer treatment now. He chose not to record other specific treatment preferences today. The plan will be revisited at the first response scan and at any change in his health. [S]